What just happened? Neuralink, the brain-implant company founded by Elon Musk, is preparing to take its most ambitious step yet. The outfit plans to begin high-volume production of its brain – computer interface this year and transition to a fully automated surgical procedure, according to a statement Musk posted on X. The move signals Neuralink's intent to shift from limited clinical trials to broader manufacturing and deployment – a transition that could define the next stage of neurotechnology's commercialization.
The announcement follows two years of accelerated testing and regulatory navigation. Neuralink launched its first human trial in 2024, two years after the US Food and Drug Administration initially rejected its bid to begin testing on safety grounds. After the company addressed the FDA's early concerns – reportedly related to the device's lithium battery, implant removal process, and surgical precision – it gained permission to proceed with trials involving patients with severe spinal cord injuries.
One of the first participants has since demonstrated the device's capabilities in real-world settings. Using Neuralink's implant, the patient was able to browse the internet, play video games, and interact on social media, all through neural signals transmitted from the brain to a computer interface.
The system works by decoding brain activity into digital commands, a process that relies on hundreds of microscopic electrodes embedded in flexible threads thinner than a human hair. Those signals are processed by an external device that interprets intent, translating thought into action on a connected computer or physical device.
Neuralink will start high-volume production of brain-computer interface devices and move to a streamlined, almost entirely automated surgical procedure in 2026.
– Elon Musk (@elonmusk) December 31, 2025
Device threads will go through the dura, without the need to remove it. This is a big deal. https://t.co/nfNmtFHKsp
In September 2025, Neuralink reported that 12 people with advanced paralysis had received the implant. These participants were able to operate digital and physical tools solely through their thoughts, providing early proof of the technology's potential to restore communication and mobility. The company also secured $650 million in new funding earlier that year, signaling investor confidence in its ability to bring BCI technology closer to practical medical use.
The next challenge lies in scaling production without compromising precision. Neuralink's proposed shift to "entirely automated" surgery could minimize variability in implantation procedures and ensure greater consistency across patients. The company's custom surgical robot already plays a central role in inserting the threads into brain tissue with sub-millimeter accuracy – a process too delicate for the human hand. Expanding that automation to the full implant procedure would mark a significant step toward reliability and commercial viability.
While Musk's post suggests an aggressive timeline, Neuralink's future depends heavily on continued regulatory approval and the demonstration of long-term safety. Automating neurosurgery also raises new questions around oversight, ethical deployment, and accessibility. Yet for the growing field of brain-computer interfaces, Neuralink's push toward mass production represents a turning point from conceptual prototypes to potentially scalable neurotechnology.
Neuralink wants to automate brain surgery and mass produce implants by 2026
